EOLS · NASDAQ
Evolus (EOLS) Stock Price & Fundamentals
Evolus (EOLS) closed at $916.22 on Oct 9, 2026, up 1.51% from the previous close of $902.57.
Share price, past year
1Y −3.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $916.22 |
| Sep 30, 2026 | $913.89 |
| Aug 31, 2026 | $953.93 |
| Jul 31, 2026 | $936.59 |
| Jun 30, 2026 | $905.46 |
| May 29, 2026 | $909.80 |
| Apr 30, 2026 | $902.79 |
| Mar 31, 2026 | $895.55 |
| Feb 27, 2026 | $891.70 |
| Jan 30, 2026 | $863.97 |
| Dec 31, 2025 | $865.12 |
| Nov 28, 2025 | $843.29 |
| Oct 31, 2025 | $894.69 |
Key statistics
- Market cap
- $60.48B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.51
- Revenue (TTM)
- $316.49M
- Net income (TTM)
- −$34.33M
- Shares outstanding
- 66M
- Dividend yield
- —
- 52-week range
- $843.06 – $960.95
Evolus's market cap is $60.48B, based on a share price of $916.22 and 66M shares outstanding as of Jun 30, 2026.
Financials
Evolus reported revenue of $297.18M for fiscal 2025, up 11.61% from fiscal 2024.
Evolus reported a net loss of $51.64M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $297.18M | +11.6% | −$51.64M | −17.4% | −$0.80 | −$45.71M |
| FY2024ended Dec 31, 2024 | $266.27M | +31.8% | −$50.42M | −18.9% | −$0.81 | −$19.47M |
| FY2023ended Dec 31, 2023 | $202.09M | +36.0% | −$61.69M | −30.5% | −$1.08 | −$34.48M |
| FY2022ended Dec 31, 2022 | $148.62M | +49.1% | −$74.41M | −50.1% | −$1.33 | −$86.53M |
| FY2021ended Dec 31, 2021 | $99.67M | +76.3% | −$46.81M | −47.0% | −$0.94 | −$33.78M |
| FY2020ended Dec 31, 2020 | $56.54M | +61.9% | −$163.01M | −288.3% | −$4.83 | −$58.69M |
| FY2019ended Dec 31, 2019 | $34.93M | — | −$90.03M | −257.8% | −$3.19 | −$93.73M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$46.87M | — | −$1.92 | −$25.68M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $84.08M | −$8.05M | −$0.12 |
| Q1 FY2026ended Mar 31, 2026 | $73.14M | −$10.67M | −$0.16 |
| Q4 FY2025ended Dec 31, 2025 | $90.30M | $130.00K | $0.01 |
| Q3 FY2025ended Sep 30, 2025 | $68.97M | −$15.74M | −$0.24 |
| Q2 FY2025ended Jun 30, 2025 | $69.39M | −$17.14M | −$0.27 |
| Q1 FY2025ended Mar 31, 2025 | $68.52M | −$18.89M | −$0.30 |
| Q4 FY2024ended Dec 31, 2024 | $78.95M | −$6.79M | −$0.11 |
| Q3 FY2024ended Sep 30, 2024 | $61.09M | −$19.17M | −$0.30 |
Company profile
- Name
- Evolus, Inc.
- Ticker
- EOLS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001570562
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Aug 4, 2026
- Jul 8, 2026
- Jun 12, 2026
- May 4, 2026
- May 4, 2026
- Mar 13, 2026
Frequently asked questions
What is Evolus's stock price?
Evolus (EOLS) closed at $916.22 on Oct 9, 2026, up 1.51% from the previous close of $902.57.
What is Evolus's market cap?
Evolus's market cap is $60.48B, based on a share price of $916.22 and 66M shares outstanding as of Jun 30, 2026.
How much revenue does Evolus make?
Evolus reported revenue of $297.18M for fiscal 2025, up 11.61% from fiscal 2024.
Does Evolus pay a dividend?
Evolus's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Evolus, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures